2020
DOI: 10.1128/msphere.00671-19
|View full text |Cite
|
Sign up to set email alerts
|

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1

Abstract: Dengue is the most prevalent arboviral disease afflicting humans, and a vaccine appears to be the most rational means of control. Dengue vaccine development is in a critical phase, with the first vaccine licensed in some countries where dengue is endemic but demonstrating insufficient efficacy in immunologically naive populations. Since virus-neutralizing antibodies do not invariably correlate with vaccine efficacy, other markers that may predict protection, including cell-mediated immunity, are urgently neede… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
4
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 57 publications
1
4
0
1
Order By: Relevance
“…Furthermore, CYD-TDV-elicited CD8+ T cells appear to be restricted to non-structural components of the vaccine derived from yellow fever virus, and are poorly cross-reactive with DENV 21 . When reconciled with our prior study assessing the CMI generated in response to a monovalent PIV (DENV-1) 25 , we conclude that formalin-inactivated PIVs induce reproducibly, detectable, and durable, albeit low frequency CD4+ T cells capable of responding to recall antigen in vitro and in vivo.…”
Section: Discussionsupporting
confidence: 58%
“…Furthermore, CYD-TDV-elicited CD8+ T cells appear to be restricted to non-structural components of the vaccine derived from yellow fever virus, and are poorly cross-reactive with DENV 21 . When reconciled with our prior study assessing the CMI generated in response to a monovalent PIV (DENV-1) 25 , we conclude that formalin-inactivated PIVs induce reproducibly, detectable, and durable, albeit low frequency CD4+ T cells capable of responding to recall antigen in vitro and in vivo.…”
Section: Discussionsupporting
confidence: 58%
“…IFNγ ELISpots-IFNγ ELISPOT assays were similarly performed as previously described. 43 In brief, cryopreserved PBMC were thawed and let to rest overnight before plating 100,000-200,000 cells per well of a PVDF (polyvinylidene di uoride) membrane plate coated with anti-IFN-γ antibody. Cells were co-incubated overnight with DHIM-1 peptide pools A-F.…”
Section: Safetymentioning
confidence: 99%
“…Another obstacle in dengue vaccine development is that virus-neutralizing antibodies do not invariably correlate with vaccine efficacy; therefore, other markers that may predict protection, including cell-mediated immunity, are urgently needed. A recent study showed the induction of DENV-specific CD4 + T cell responses after vaccination with a monovalent purified inactivated virus (PIV) vaccine candidate against DENV-1 adjuvanted with alum ( Friberg et al, 2020 ). A better understanding of antibody responses that correlate with protection against DENV infection by all four serotypes is of great importance for developing a uniformly effective vaccine ( Martinez et al, 2021 ).…”
Section: Challenges To Overcome In Denv Vaccine Developmentmentioning
confidence: 99%